Corporate Banner
Satellite Banner
Technology Networks Header
Friday, August 01, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
UTSW Cancer Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation
Irreversible inhibitor for KRAS gene mutation involved in lung, colon, and pancreatic cancers.
Bowel Cancer Breakthrough May Benefit Thousands of Patients
Researchers at Queen’s University have discovered how two genes cause bowel cancer cells to become resistant to treatments used against the disease.
Study Finds Low Oxygen Environment Helps Tumors Silence Critical Genes
The study led by Yale Cancer Center may provide clues to how some aggressive cancers turn off, or silence, genes critical to suppressing tumors.
Researchers Uncover New Cancer Cell Vulnerability
The research showed that telomerase-expressing cells depend upon a gene named p21 for their survival.
Self-assembling Nanoparticle Could Improve MRI Scanning for Cancer Diagnosis
Scientists have designed the nanoparticle that targets tumours, to help doctors diagnose cancer earlier.
Wisconsin Scientists Find Genetic Recipe to Turn Stem Cells to Blood
The ability to reliably and safely make in the laboratory all of the different types of cells in human blood is one key step closer to reality.
Capturing Cancer: A Powerful New Technique for Early Diagnosis
Researchers describe an innovative technique for early disease detection, which they call immunosignaturing.
Study Identifies Novel Genomic Changes in the Most Common Type of Lung Cancer
TCGA finds mutations in a key cancer-causing pathway, expanding targets for existing drugs.
Low Doses of Arsenic Cause Cancer in Male Mice
NIH researchers found that arsenic in drinking water develop lung cancer.
Brain Tumor Invasion Along Blood Vessels May Lead to New Cancer Treatments
NIH-funded researchers find brain tumor cells disrupt the brain’s protective barrier, offering potential avenues for therapy.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv